Tumor Genetic Screening Programs: A Call to Action

that although 39% of patients had at least one potentially actionable alteration, only 11% of these patients (4% of patients overall) were subsequentlyenrolledontoagenomicallymatchedstudy.Theactionablegenomicalterationsthatmostcommonlypromptedenrolledtoa genotype-matched trial were mutations in PIK3CA (41%), BRAF (28%), EGFR (8%), KRAS (5%), and ERBB2 (5%). Interestingly, patientswithanactionablealterationwereonlymarginallymorelikelyto enrollontoaclinicaltrial(eithermatchedorunmatched)whencompared with patients without an actionable alteration (28.4% v24.4%). This prospective tumor profiling effort was conducted at a large cancer center with an extensive clinical trial portfolio. Therefore, we are forced to consider whether the 4% enrollment rate to a genotypematched study may be the upper limit of what can expected from similarprofilingeffortsinadiversepatientpopulation.Itisimportant